SG Americas Securities LLC Has $702,000 Stock Position in Xencor, Inc. (NASDAQ:XNCR)

SG Americas Securities LLC decreased its position in shares of Xencor, Inc. (NASDAQ:XNCR) by 4.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 30,555 shares of the biopharmaceutical company’s stock after selling 1,332 shares during the period. SG Americas Securities LLC’s holdings in Xencor were worth $702,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of XNCR. Point72 Asset Management L.P. boosted its position in Xencor by 147.3% during the third quarter. Point72 Asset Management L.P. now owns 3,120,229 shares of the biopharmaceutical company’s stock valued at $62,748,000 after purchasing an additional 1,858,440 shares during the last quarter. RA Capital Management L.P. acquired a new stake in Xencor during the third quarter valued at $11,563,000. RTW Investments LP acquired a new stake in Xencor during the third quarter valued at $11,563,000. Braidwell LP acquired a new stake in Xencor during the third quarter valued at $9,380,000. Finally, Erste Asset Management GmbH acquired a new stake in Xencor during the third quarter valued at $7,087,000.

Insider Activity at Xencor

In related news, VP John R. Desjarlais sold 68,684 shares of the business’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $23.48, for a total transaction of $1,612,700.32. Following the transaction, the vice president now directly owns 200,104 shares in the company, valued at $4,698,441.92. The trade was a 25.55 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Bassil I. Dahiyat sold 3,366 shares of the business’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $24.02, for a total value of $80,851.32. Following the transaction, the chief executive officer now owns 352,615 shares in the company, valued at $8,469,812.30. This represents a 0.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 136,050 shares of company stock worth $3,277,609 over the last three months. Company insiders own 5.23% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have weighed in on XNCR shares. BMO Capital Markets reaffirmed an “outperform” rating and issued a $34.00 price target (up previously from $32.00) on shares of Xencor in a research report on Friday, November 8th. Piper Sandler raised Xencor from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $20.00 to $30.00 in a research report on Monday, December 2nd. JPMorgan Chase & Co. boosted their price target on Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Wedbush reaffirmed an “outperform” rating and issued a $38.00 price target on shares of Xencor in a research report on Thursday, November 7th. Finally, Wells Fargo & Company started coverage on Xencor in a research report on Thursday, December 12th. They issued an “overweight” rating and a $37.00 price target for the company. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Xencor presently has a consensus rating of “Buy” and a consensus price target of $34.88.

Xencor Price Performance

NASDAQ XNCR opened at $18.83 on Thursday. Xencor, Inc. has a twelve month low of $15.31 and a twelve month high of $27.24. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. The stock has a market capitalization of $1.32 billion, a PE ratio of -5.88 and a beta of 0.72. The stock has a 50-day simple moving average of $23.30 and a 200 day simple moving average of $21.07.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.98) by $0.27. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The firm had revenue of $10.70 million for the quarter, compared to analyst estimates of $14.59 million. During the same period in the previous year, the company posted ($0.40) earnings per share. The company’s quarterly revenue was down 81.9% compared to the same quarter last year. Research analysts anticipate that Xencor, Inc. will post -3.68 EPS for the current year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.